OAM
GNMX

Oxford Asset Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Oxford Asset Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-47,995
Closed -$249K – 1525
2016
Q4 		$249K Buy
47,995
+36,728
+326% +$193K 0.01% 679
2016
Q3 		$63K Sell
11,267
-11,792
-51% -$67.2K ﹤0.01% 747
2016
Q2 		$128K Buy
+23,059
New +$121K ﹤0.01% 724

Other funds holding GNMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oxford Asset Management's GNMX Position: Q1 2017 in Review

Oxford Asset Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2017, closing a stake of 47,995 shares — an estimated $249K sold.

Oxford Asset Management first reported a position in GNMX in Q2 2016 and held it in 3 quarters. The position peaked at $249K in Q4 2016. 73 funds tracked by Wall St. Rank hold GNMX as of Q1 2017.

  • Oxford Asset Management reported no remaining Aevi Genomic Medicine Inc position as of Q1 2017 after selling out during the quarter.
  • Oxford Asset Management sold 47,995 Aevi Genomic Medicine Inc shares in Q1 2017, an estimated $249K.
  • Oxford Asset Management first reported a position in Aevi Genomic Medicine Inc in Q2 2016 and held it in 3 quarters.
  • Oxford Asset Management's Aevi Genomic Medicine Inc position peaked at $249K in Q4 2016.
  • 73 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2017.

Based on Oxford Asset Management's 13F filing for Q1 2017, filed 9 May 2017.